Chronic myeloid leukemia relapsing ten years after allogenic bone marrow transplantation

  • HINO Yutaro
    Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital
  • DOKI Noriko
    Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital
  • YAMAMOTO Keita
    Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital
  • SENOO Yasushi
    Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital
  • SASAJIMA Satoshi
    Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital
  • SAKAGUCHI Masahiro
    Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital
  • HATTORI Keiichiro
    Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital
  • KAITO Satoshi
    Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital
  • KUROSAWA Shuhei
    Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital
  • HARADA Kaito
    Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital
  • IKEGAWA Shuntaro
    Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital
  • WATANABE Daisuke
    Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital
  • HAGINO Takeshi
    Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital
  • YOSHIOKA Kosuke
    Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital
  • WATAKABE Kyoko
    Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital
  • IGARASHI Aiko
    Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital
  • NAJIMA Yuho
    Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital
  • KOBAYASHI Takeshi
    Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital
  • KAKIHANA Kazuhiko
    Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital
  • SAKAMAKI Hisashi
    Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital
  • OHASHI Kazuteru
    Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital

Bibliographic Information

Other Title
  • 同種骨髄移植後10年で晩期再発した慢性骨髄性白血病
  • 症例報告 同種骨髄移植後10年で晩期再発した慢性骨髄性白血病
  • ショウレイ ホウコク ドウシュ コツズイ イショク ゴ 10ネン デ バンキ サイハツ シタ マンセイ コツズイセイ ハッケツビョウ

Search this article

Abstract

A 58-year-old female was diagnosed with Philadelphia chromosome positive chronic myeloid leukemia (CML) in blast crisis (BC) in 2004. The patient received imatinib, which quickly induced molecular remission, and subsequently underwent bone marrow transplantation (BMT) from an unrelated human leukocyte antigen (HLA)-identical donor. The post-transplant clinical course was essentially uneventful. In 2014, ten years after the BMT, the patient was admitted to our hospital complaining of lymphadenopathy, and blasts were observed in peripheral blood. The patient was diagnosed as having a CML relapse in myeloid BC, with leukemic infiltration in lymph nodes, and was treated with dasatinib. Subsequently, pleural effusion developed and nilotinib was administered, which induced normal blood counts without blasts and partial cytogenetic remission, one month after administration. Six months after the relapse, this patient underwent a second BMT from an HLA-matched unrelated donor. Recent studies have demonstrated the cumulative incidence of CML relapse more than five years after allogeneic hematopoietic stem cell transplantation (allo-HSCT) to be higher than in acute myeloid leukemia. Although rare, the possibility of late relapse should be considered in patients diagnosed with CML after allo-HSCT.

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 57 (5), 608-612, 2016

    The Japanese Society of Hematology

Details 詳細情報について

Report a problem

Back to top